Eli Lilly has expanded its partnership with Oblique Therapeutics, adding a second strand to an alliance focused on using the AbiProt platform to discover antibodies against high-value targets. Oblique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback